FDA Okays VEGF Drug for Diabetic Retinopathy
(MedPage Today) -- Lucentis wins an indication in diabetic retinopathy. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 6, 2015 Category: Primary Care Source Type: news
Paid to Promote Eye Drug, and Prescribing It Widely
Half of the 20 doctors who received the most money from Genentech to promote its drug Lucentis in 2013 were among the highest users of the drug in 2012, a federal database shows. (Source: NYT Health)
Source: NYT Health - December 8, 2014 Category: Consumer Health News Authors: By KATIE THOMAS and RACHEL ABRAMS Tags: Medicare Lucentis (Drug) Doctors Roche Holding AG RHHBY Other OTC Macular Degeneration Genentech Inc Avastin (Drug) Source Type: news
NHS: Scandal of the sight saving drug doctors are not allowed to prescribe
Bill Organ’s sight was saved by injections of the drugs Avastin and Lucentis. Both drugs stop the loss of central vision caused by age-related macular degeneration (AMD). (Source: the Mail online | Health)
Source: the Mail online | Health - November 25, 2014 Category: Consumer Health News Source Type: news
Ranibizumab preferred option in myopic CNV
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2014 Category: Drugs & Pharmacology Source Type: news
Regeneron's Eylea Works Better vs Avastin and Lucentis in StudyRegeneron's Eylea Works Better vs Avastin and Lucentis in Study
Regeneron Pharmaceuticals said its drug Eylea (aflibercept) for diabetic macular edema produced significantly greater improvement in visual acuity from baseline to 52 weeks compared with Genentech's Avastin (bevacizumab) and Lucentis (ranibizumab). Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - October 21, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news
EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
TARRYTOWN, N.Y., Oct. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network (DRCR.net)... Biopharmaceuticals, OphthalmologyRegeneron Pharmaceuticals, EYLEA, aflibercept, Diabetic Macular Edema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 17, 2014 Category: Pharmaceuticals Source Type: news
Regeneron's Eylea works better vs Avastin and Lucentis in study
(Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis. (Source: Reuters: Health)
Source: Reuters: Health - October 17, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
FDA grants Priority Review for Lucentis in diabetic retinopathy
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted to file the company's supplemental Biologics License Application (sBLA) and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans. The FDA confirmed action date is February 6, 2015. (Source: Roche Investor Update)
Source: Roche Investor Update - October 8, 2014 Category: Pharmaceuticals Source Type: news
Limit Ranibizumab Injections in Macular DegenerationLimit Ranibizumab Injections in Macular Degeneration
Investigators have identified an optimum number of injections of the vascular endothelial growth factor inhibitor for wet age-related macular degeneration in the first year of treatment. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Risk Factors for Geographic Atrophy in the CATT TrialRisk Factors for Geographic Atrophy in the CATT Trial
The CATT results are discussed -- will they help ophthalmologists choose either bevacizumab or ranibizumab? Medscape Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 19, 2014 Category: Opthalmology Tags: Ophthalmology Viewpoint Source Type: news
Cheaper alternative to licensed drug for treating eye disease has similar side-effects
(Wiley) Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2014 Category: Global & Universal Source Type: news
Prompt or Delayed Laser Equal in Diabetic Macular EdemaPrompt or Delayed Laser Equal in Diabetic Macular Edema
For patients receiving intravitreal ranibizumab, the timing of laser treatment for diabetic macular edema has little effect on outcome, report researchers. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Ranibizumab vs Laser in Diabetic Macular EdemaRanibizumab vs Laser in Diabetic Macular Edema
Are the differences significant enough to subject patients to the high injection burden required for anti-VEGF treatment? Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 6, 2014 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news
More Safety Data Needed for Intravitreal Anti-VEGF AgentsMore Safety Data Needed for Intravitreal Anti-VEGF Agents
Intravitreal use of bevacizumab and ranibizumab does not appear to cause major cardiovascular events or non-ocular bleeding in patients with eye disease, according to a meta-analysis from France. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 5, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
